These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 20943071)

  • 21. Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis.
    Aboulafia DM; Bundow D; Wilske K; Ochs UI
    Mayo Clin Proc; 2000 Oct; 75(10):1093-8. PubMed ID: 11040859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.
    Kamarashev J; Lor P; Forster A; Heinzerling L; Burg G; Nestle FO
    Dermatology; 2002; 205(2):213-6. PubMed ID: 12218252
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Etanercept for psoriasis: two case reports.
    Fidalgo A; Baptista J; Rocha Páris F; Caldas Lopes L; Ferreira A
    Int J Clin Pharmacol Res; 2005; 25(4):159-63. PubMed ID: 16402631
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.
    Strober B; Teller C; Yamauchi P; Miller JL; Hooper M; Yang YC; Dann F
    Br J Dermatol; 2008 Aug; 159(2):322-30. PubMed ID: 18503600
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of erythrodermic psoriasis with etanercept.
    Esposito M; Mazzotta A; de Felice C; Papoutsaki M; Chimenti S
    Br J Dermatol; 2006 Jul; 155(1):156-9. PubMed ID: 16792768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of etanercept in patients with psoriasis and hepatitis C.
    Ventura F; Gomes J; Duarte Mda L; Fernandes JC; Brito C
    Eur J Dermatol; 2010; 20(6):808-9. PubMed ID: 20923749
    [No Abstract]   [Full Text] [Related]  

  • 27. Treatment of psoriatic arthritis and recalcitrant skin disease with combination therapy.
    Hamilton TK
    J Drugs Dermatol; 2008 Nov; 7(11):1089-93. PubMed ID: 19110745
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of etanercept therapy in a patient with psoriasis, Down's syndrome and concomitant hepatitis C virus infection.
    Alcaide AJ; Barrera MV; Habicheyn S; López N; Mendiola MV; Herrera E
    J Eur Acad Dermatol Venereol; 2008 Dec; 22(12):1514-6. PubMed ID: 18355196
    [No Abstract]   [Full Text] [Related]  

  • 29. Etanercept for the treatment of psoriasis: combination therapy with other modalities.
    Strober BE; Clarke S
    J Drugs Dermatol; 2004; 3(3):270-2. PubMed ID: 15176161
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Etanercept for psoriasis and psoriatic arthritis in a patient with Charcot-Marie-Tooth disease.
    Guarneri C; Russo M; Mazzeo A; Cannavò SP
    Ann Pharmacother; 2014 Apr; 48(4):550-1. PubMed ID: 24658637
    [No Abstract]   [Full Text] [Related]  

  • 31. Adverse reactions during biological drug therapy in psoriasis:clinical series and a review of the literature.
    Montesu MA; Addis GM; Satta R; Cottoni F
    G Ital Dermatol Venereol; 2011 Aug; 146(4):273-81. PubMed ID: 21785393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis.
    Mease PJ
    Skin Therapy Lett; 2003 Jan; 8(1):1-4. PubMed ID: 12728284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Psoriasis and psoriatic rheumatism: effectiveness of etanercept for cutaneous and joint lesions].
    Paul C; Solignac M
    Ann Dermatol Venereol; 2010 Apr; 137(4 Suppl):13-5. PubMed ID: 20510165
    [No Abstract]   [Full Text] [Related]  

  • 34. Retrospective Study of Patients on Etanercept Therapy for Rheumatic Diseases in Patients With Chronic Hepatitis C Virus.
    Gandhi NP; Manadan AM; Block JA
    J Clin Rheumatol; 2017 Aug; 23(5):252-257. PubMed ID: 28700530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Long-term safety and efficacy of etanercept in the treatment of psoriasis].
    Zaragoza V; Pérez A; Sánchez JL; Oliver V; Martínez L; Alegre V
    Actas Dermosifiliogr; 2010; 101(1):47-53. PubMed ID: 20109392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful clearance of hepatitis C virus with pegylated interferon α-2a and ribavirin in an etanercept-treated patient with psoriatic arthritis, hepatitis B virus coinfection and latent tuberculosis.
    Mederacke I; Witte T; Wedemeyer H; Meyer-Olson D
    Ann Rheum Dis; 2011 Jul; 70(7):1343-4. PubMed ID: 21131645
    [No Abstract]   [Full Text] [Related]  

  • 37. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
    Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J
    J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept.
    Kanelleas A; Liapi C; Katoulis A; Stavropoulos P; Avgerinou G; Georgala S; Economopoulos T; Stavrianeas NG; Katsambas A
    Clin Exp Dermatol; 2011 Dec; 36(8):845-50. PubMed ID: 21790728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful treatment with etanercept of a patient with psoriatic arthritis after adalimumab-related hepatotoxicity.
    Massarotti M; Marasini B
    Int J Immunopathol Pharmacol; 2009; 22(2):547-9. PubMed ID: 19505409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Etanercept combined with methotrexate for high-need psoriasis.
    Driessen RJ; van de Kerkhof PC; de Jong EM
    Br J Dermatol; 2008 Aug; 159(2):460-3. PubMed ID: 18547310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.